International Cancer Survivorship Symposium

Thursday, February 3, 2022, 9 a.m. to 5 p.m. – Auditorium Ettore Rossi, Kinderkliniken, Inselspital, 3010 Bern

Fast-evolving treatment options and technologies continue to advance survival in children, adolescents, and young adults diagnosed with cancer. The International Cancer Survivor Symposium will bring together primary care physicians, oncologists for adults and children, other specialty physicians, researchers, psychologists and allied-health professionals to discuss latest developments and future directions of care for cancer survivors. The program will focus on late effects, follow-up care and chronic diseases, fatigue, psychosocial aspects, and fertility.

We look forward to welcoming you to the first International Cancer Survivorship Symposium organized in Bern/Switzerland by the University Cancer Center Inselspital (UCI), the Department of General Internal Medicine, the Division of Pediatric Hematology and Oncology (all at the Inselspital, Bern), the Institute of Social and Preventive Medicine, University of Bern, and the Department of Health Sciences and Medicine, University of Lucerne.


Follow-up care
Guest Lecture: Prof. Melissa Hudson, MD, St. Jude Children's Research Hospital, Memphis, USA

Late effects and chronic disease after treatment for childhood and AYA cancer
Guest Lecture: Prof. Melissa Hudson, MD, St. Jude Children's Research Hospital, Memphis, USA

Fatigue / psychosocial problems
Guest Lecture: Dr. Jacqueline Loonen, Radboud University Medical Center, Nijmegen, Netherlands

Guest Lecture: Prof. Michael von Wolff, Department of Gynaecology and Obstetrics, Inselspital Bern, University Hospital, Bern, Switzerland


Prof. Melissa Hudson

Melissa Hudson

Director Cancer Survivorship Division in the Department of Oncology and Co-Leader Cancer Control & Survivorship Program St. Jude USA

Melissa M. Hudson, MD, is currently a Member and Director of the Cancer Survivorship Division in the Department of Oncology and holds the Charles E. Williams Endowed Chair of Oncology-Cancer Survivorship. She directs the St. Jude After Completion of Therapy (ACT) Program, which now monitors over 6000 long-term childhood cancer survivors treated on St. Jude trials.

Dr. Hudson disseminated the St. Jude model of risk-based survivor care in her role as Co-Chair of the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer and Co-Chair of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG). She is also the Chair of the Education Committee of the Childhood Cancer Survivor Study (CCSS) and a member of the CCSS Executive Committee.

She works collaboratively with multidisciplinary investigators at St. Jude and within COG, IGHG and the CCSS in research initiatives evaluating biomedical and psychosocial outcomes among childhood cancer survivors and translating data from health outcomes research into evidence-informed clinical practice guidelines and interventions to improve the quality and duration of survival after childhood cancer.

She has published widely on her research initiatives in pediatric Hodgkin lymphoma, late treatment sequelae after childhood cancer, and health surveillance of childhood cancer survivors.

Dr. Jacqueline Loonen

Jacqueline Loonen

Pediatric oncologist and head of the Radboudumc Center of Expertise Cancer Survivorship.


Radboud University Medical Center, Nijmegen, The Netherlands
Department of Hematology


My main interest and expertise is cancer survivorship care (CSC). In the Radboudumc Center of Expertise Cancer Survivorship I implemented an innovative care model for CSC: the “Personalized Cancer Survivorship Care model”, which comprises a multidisciplinary care infrastructure based on (international) guidelines and Person Centred Care.

I am a member of the core group of the Dutch Childhood Cancer Survivor Study LATER (DCCSS LATER) and project leader of the DCCSS LATER studies on: Cancer related fatigue, male fertility, benign skin disorders, and hypofunction of the spleen. As a consortium member of the PanCareFollowUp project I am work-package leader of the work-package on life style intervention and Person Centred Care.

Prof. Dr. med. Michael von Wolff

Michael von Wolff

Michael von Wolff is Head of the Division of Gynaecological Endocrinology and Reproductive Medicine at the Women's University Hospital, Berne, Switzerland.

Regarding fertility preservation he has established the German speaking network of fertility preservation before cytotoxic therapies “FertiPROTEKT” ( in 2006. Furthermore he had founded the ESHRE Task Force on fertility preservation, has co-founded the ESHRE SIG “Fertility preservation” and is Vice president of the ISFP since 2021. He is also President of the Swiss society of Reproductive Medicine since 2019. 

In fertility preservation he focuses on ovarian stimulation and ovarian tissue transplantation. To provide physicians with practical guidelines to indicate and perform fertility preservation he has published the book “Fertility preservation on oncological and non-oncological diseases – a practical guide”, Springer, 2020. 


We are happy to announce the first Cancer Survivor Scientific Research Award.
A scientific committee will select the best three scientific presentions during the meeting.

Abstract Submission

To submit a contribution follow the Link
Deadline: November 21, 2021.

The Scientific Committee

  • Prof. Dr. Maria Wertli & PD Dr. Christine Baumgartner, Department of General Internal Medicine, Inselspital Bern
  • Dr. Eva Maria Tinner & Prof. Dr. Jochen Rössler, Division of Pediatric Hematology and Oncology, Inselspital Bern
  • Prof. Dr. Claudia Kuehni, Institute of Social and Preventive Medicine (ISPM), University of Bern
  • Prof. Dr. Gisela Michel, Department Health Sciences and Medicine, University of Lucerne